Article

Novartis to market antibody fragment

Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
REGENXBIO launches phase 2b/3 trial of sura-vec for diabetic retinopathy
August 13th 2025

REGENXBIO launches phase 2b/3 trial of sura-vec for diabetic retinopathy

3 Things You Should Know About the GA Pipeline
August 13th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI
August 13th 2025

Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 13th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight
August 13th 2025

What the eyes reveal: Cardiovascular clues in women—hidden in plain sight

(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 13th 2025

Robotic precision: Elevating the state of laser cataract surgery

© 2025 MJH Life Sciences

All rights reserved.